Patent ID: 8026055

Claim:
A method of prognosing a subject with early stage non-small cell lung cancer (NSCLC), comprising the steps of: (a) determining the expression levels of STX1A, HIF1A, CCT3, MAFK, RNF5 and HLA-DPB1 in a lung tumor test sample from the subject; and (b) comparing the expression levels so determined with expression levels of STX1A, HIF1A, CCT3, MAFK, RNF5 and HLA-DPB1 in a lung tumor control from an early stage NSCLC subject or group of early stage NSCLC subjects, wherein higher levels of STX1A, HIF1A, CCT3, MAFK, and RNF5 and lower levels of HLA-DPB1 in the subject as compared to the control indicates a poor prognosis; or (c) determining the expression levels of STX1A, CCR7, and HIF1A in a lung tumor test sample from the subject; and (d) comparing the expression levels so determined with expression levels of STX1A, CCR7, and HIF1A in a control from an early stage NSCLC subject or group of early stage NSCLC subjects, wherein higher levels of STX1A and HIF1A and lower levels of CCR7 in the subject as compared to the control indicates a poor prognosis.